With its recent approval of Nexviazyme (avalglucosidase alfa-ngpt), Sanofi (NSDQ:SNY) has asserted its control over the Pompe disease landscape. In 2006, FDA approved Genzyme’s Myozyme (alglucosidase alfa) for Pompe disease. Sanofi acquired the company a decade ago. Additionally, FDA approved Lumizyme in 2010, which uses the same biologic, but is indicated for patients eight years of…